Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 December 2020Website:
http://www.bioatla.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:22:25 GMTDividend
Analysts recommendations
Institutional Ownership
BCAB Latest News
BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with Context Therapeutics providing some runway extension. The company's cash position poses a significant risk, necessitating future fundraising, and potentially leading to substantial dilution and market volatility.
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA.
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE.
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Arthur He - H.C. Wainwright Operator Good day, everyone.
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug
BioAtla, Inc. (NASDAQ: BCAB) held its Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. Key participants included Bruce Mackle from LifeSci Advisors, Jay Short as Chairman, CEO, and Co-Founder, Eric Sievers as Chief Medical Officer, Sheri Lydick as Chief Commercial Officer, and Richard Waldron as Chief Financial Officer. Conference call attendees included Brian Cheng from JPMorgan, Dev Prasad from Jefferies, Kaveri Pohlman from BTIG, Arthur He from H.C. Wainwright, and Tony Butler from EF Hutton. The call began with greetings and introductions for the BioAtla First Quarter 2024 Earnings Call.
What type of business is BioAtla?
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
What sector is BioAtla in?
BioAtla is in the Healthcare sector
What industry is BioAtla in?
BioAtla is in the Biotechnology industry
What country is BioAtla from?
BioAtla is headquartered in United States
When did BioAtla go public?
BioAtla initial public offering (IPO) was on 16 December 2020
What is BioAtla website?
https://www.bioatla.com
Is BioAtla in the S&P 500?
No, BioAtla is not included in the S&P 500 index
Is BioAtla in the NASDAQ 100?
No, BioAtla is not included in the NASDAQ 100 index
Is BioAtla in the Dow Jones?
No, BioAtla is not included in the Dow Jones index
When was BioAtla the previous earnings report?
No data
When does BioAtla earnings report?
The next expected earnings date for BioAtla is 07 November 2024